Company Profile

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE391.903.6 (+0.93 % )
PREV CLOSE (Rs.) 388.30
OPEN PRICE (Rs.) 390.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 78762
TODAY'S LOW / HIGH (Rs.)388.65 397.50
52 WK LOW / HIGH (Rs.)211.3 410.35
NSE391.95 3.5 (+0.9 % )
PREV CLOSE(Rs.) 388.45
OPEN PRICE (Rs.) 388.45
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 391.95 (45 )
VOLUME 2877135
TODAY'S LOW / HIGH(Rs.) 388.40 397.45
52 WK LOW / HIGH (Rs.)211.05 410.45

Company News

Date Heading Details
22-Jun-2020 Biocon's arm, DKSH collaborate to commercialize seven generic formulations in South East Asia markets <p align="justify">Biocon's subsidiary--Biocon Pharma and DKSH Business Unit Healthcare, have signed an agreement under which DKSH will sell and distribute seven of Biocon Pharma's generic formulations in Singapore and Thailand. This development is in line with Biocon's strategy for expansion of its generic formulations business through licensing of its drug products in multiple markets. Thailand and Singapore are the two large markets in the South East Asia region.</p><p align="justify">Under the terms of the agreement, DKSH will gain an exclusive license to register and commercialize these seven generic formulations from various therapeutic areas like diabetology, cardiology, oncology and immunology, which will be sold under Biocon's brand in Singapore and Thailand. DKSH will manage marketing and sales as well as logistics for Biocon Pharma, helping drive sales growth through its capabilities and strengths in the medical and pharmacy channels. </p><p align="justify">Biocon is India's largest and Asia's leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovationdriven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.</p><p align="justify"><br></p>
22-Jun-2020 Biocon informs about press release <p align="justify">Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, Biocon has informed that it has enclosed the press release as on 22nd June 2020 titled ‘Pharma and DKSH Collaborate to commercialize seven generic formulations in South East Asia markets'. The above information will also be available on the website of the Company at www.biocon.com.</p><p align="justify">The above information is a part of company's filings submitted to BSE.</p>
22-Jun-2020 Biocon surges as its arm collaborates with DKSH <div align="justify">Biocon is currently trading at Rs. 387.50, up by 6.00 points or 1.57% from its previous closing of Rs. 381.50 on the BSE.<br></div><div align="justify"><br></div><div align="justify">The scrip opened at Rs. 382.00 and has touched a high and low of Rs. 389.10 and Rs. 382.00 respectively. So far 153776 shares were traded on the counter.<br><br></div><div align="justify">The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 404.50 on 18-Jun-2020 and a 52 week low of Rs. 211.30 on 20-Aug-2019.<br><br></div><div align="justify">Last one week high and low of the scrip stood at Rs. 404.50 and Rs. 378.10 respectively. The current market cap of the company is Rs. 46122.00 crore.<br><br></div><div align="justify">The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 22.30% and 17.03% respectively.</div><div align="justify"><br>Biocon's subsidiary--Biocon Pharma and DKSH Business Unit Healthcare, have signed an agreement under which DKSH will sell and distribute seven of Biocon Pharma's generic formulations in Singapore and Thailand. This development is in line with Biocon's strategy for expansion of its generic formulations business through licensing of its drug products in multiple markets. Thailand and Singapore are the two large markets in the South East Asia region.<br><br></div><div align="justify">Under the terms of the agreement, DKSH will gain an exclusive license to register and commercialize these seven generic formulations from various therapeutic areas like diabetology, cardiology, oncology and immunology, which will be sold under Biocon's brand in Singapore and Thailand. DKSH will manage marketing and sales as well as logistics for Biocon Pharma, helping drive sales growth through its capabilities and strengths in the medical and pharmacy channels. <br><br></div><div align="justify">Biocon is India's largest and Asia's leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovationdriven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.<br></div>
12-Jun-2020 Biocon, Mylan get USFDA's approval for insulin glargine injection ‘Semglee' <p align="justify">Biocon and Mylan N.V. have received an approval from the US Food and Drug Administration (USFDA) for the New Drug Application (NDA) for Semglee (insulin glargine injection), in vial and prefilled pen presentations, to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes. Semglee has an identical amino acid sequence to Sanofi's Lantus and is approved for the same indications.</p><p align="justify">Semglee, codeveloped by Mylan and Biocon Biologics, was approved as a drug product under the 505(b)(2) NDA pathway and is now deemed a biologic under section 351(a) in accordance with the Biologics Price Competition and Innovation Act in line with other insulin products.</p><p align="justify">Biocon is India's largest and Asia's leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovationdriven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.<br></p>
12-Jun-2020 Biocon inches up on the BSE <p align="justify">Biocon is currently trading at Rs. 387.55, up by 0.65 points or 0.17% from its previous closing of Rs. 386.90 on the BSE.</p><p align="justify">The scrip opened at Rs. 383.00 and has touched a high and low of Rs. 396.00 and Rs. 383.00 respectively. </p><p align="justify">The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 400.35 on 05-Jun-2020 and a 52 week low of Rs. 211.30 on 20-Aug-2019.</p><p align="justify">Last one week high and low of the scrip stood at Rs. 396.00 and Rs. 378.10 respectively. The current market cap of the company is Rs. 46428.00 crore.</p><p align="justify">The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 22.30% and 17.03% respectively.</p><p align="justify">Biocon and Mylan N.V. have received an approval from the US Food and Drug Administration (USFDA) for the New Drug Application (NDA) for Semglee (insulin glargine injection), in vial and prefilled pen presentations, to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes. Semglee has an identical amino acid sequence to Sanofi's Lantus and is approved for the same indications.</p><p align="justify">Semglee, codeveloped by Mylan and Biocon Biologics, was approved as a drug product under the 505(b)(2) NDA pathway and is now deemed a biologic under section 351(a) in accordance with the Biologics Price Competition and Innovation Act in line with other insulin products.</p><p align="justify">Biocon is India's largest and Asia's leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovationdriven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.<br></p>
12-Jun-2020 Biocon, Wipro and Lupin to see some action today <p><strong>Biocon </strong>and Mylan N.V. have received an approval from the US Food and Drug Administration (USFDA) for the New Drug Application (NDA) for Semglee (insulin glargine injection), in vial and pre-filled pen presentations, to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes. Semglee has an identical amino acid sequence to Sanofi's Lantus and is approved for the same indications.</p><p><strong>Wipro</strong> has entered into partnership with CloudKnox Security. The Wipro and CloudKnox joint solution offering enables enterprises to proactively protect and manage their Hybrid and Multi-Cloud infrastructure by continuously detecting and remediating over-permissioned identities. The company will offer an Access Governance for Hybrid Cloud ‘as-a-service' offering, powered by CloudKnox. The company will leverage its NextGen Cyber Defense Centers to deliver the service. This offering provides continuous protection of critical cloud resources for customers by enforcing least privilege policies. </p><p><strong>Lupin</strong> has received approval for its Albendazole Tablets USP, 200 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Albenza Tablets, 200 mg, of Impax Laboratories Inc. Albendazole Tablets USP, 200 mg, are an anthelmintic drug indicated for treatment of Parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm and for Cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm.</p><p><strong>Kirloskar Ferrous Industries</strong> has commissioned the operations of 20 MW Power Generation plant attached to the Coke Oven Plant situated at Bevinahalli Village, District Koppal, Karnataka on June 11, 2020 by following the COVID-19 Guidelines issued by the Government of India, the State Government and the Local Authorities. The power will be generated by using waste gas generated from the Coke Oven Plant. It will be utilized primarily for captive consumption resulting in reduction of power cost.</p><p><strong>Mitsu Chem Plast</strong> has launched yet another innovative product ‘Dontouch Corona Sword' in its long-standing range of innovative products. This product is going to be very useful for Indians in fight against Covid-19. Dontouch is the product which allows users to do their various day to day activities hygienically without touching any contaminated surfaces. This product is having various usage applications like Door Opening, Handshake, Bus or Train Handle, Car Steering, Lifting Bags, Toilet Flush, Lift Buttons, Card Swipe Machines, ATMs, Switch On/Off etc.</p><p><strong>Arvind</strong> has launched Anti-Viral Textile technology for the First time in India under its brand ‘Intellifabrix'. The company has partnered with Swiss Textile Innovation leader HeiQ Materials AG in association with Taiwanese Specialty chemical major Jintex Corporation to introduce this revolutionary anti-virus technology in India.</p><p><strong>Mahindra &amp; Mahindra</strong> (M&amp;M) has pledged its support to the frontline Covid caretakers and essential service providers, who are providing unparalleled support during this ongoing Covid pandemic, by offering a host of affordable finance schemes on all its vehicles. As an industry first, the company has rolled out its offers to an entire range of essential service providers that includes Journalists/Media Professionals, Railway/Airline Staff and others, beyond Doctors, Nurses, Paramedics, Government Officials and Policemen. <br></p>
27-May-2020 Biocon's arm gets DCGI's nod for emergency use of CytoSorb to treat critical Covid-19 patients <p align="justify">Biocon's subsidiary -- Biocon Biologics has received the Drugs Controller General of India's (DCGI) approval for an extracorporeal blood purification (EBP) device CytoSorb to reduce pro-inflammatory cytokines levels in confirmed COVID-19 patients admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure.</p><p align="justify">Biocon Biologics has been granted licence for emergency use of CytoSorb in public interest by the Indian health regulator to treat COVID-19 patients who are 18 years of age or older. The licence will be effective until control of the COVID-19 outbreak in the country.</p><p align="justify">Biocon is India's largest and Asia's leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide. <br></p>
27-May-2020 Biocon inches up as its arm gets DCGI's nod for emergency use of CytoSorb to treat critical Covid-19 patients <p align="justify">Biocon is currently trading at Rs. 358.80, up by 0.20 points or 0.06% from its previous closing of Rs. 358.60 on the BSE.</p><p align="justify">The scrip opened at Rs. 358.60 and has touched a high and low of Rs. 363.10 and Rs. 357.50 respectively. So far 11648 shares were traded on the counter.</p><p align="justify">The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 367.80 on 20-Apr-2020 and a 52 week low of Rs. 211.30 on 20-Aug-2019.</p><p align="justify">Last one week high and low of the scrip stood at Rs. 363.10 and Rs. 345.00 respectively. The current market cap of the company is Rs. 43032.00 crore.</p><p align="justify">The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 22.30% and 17.03% respectively.</p><p align="justify">Biocon's subsidiary -- Biocon Biologics has received the Drugs Controller General of India's (DCGI) approval for an extracorporeal blood purification (EBP) device CytoSorb to reduce pro-inflammatory cytokines levels in confirmed COVID-19 patients admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure.</p><p align="justify">Biocon Biologics has been granted licence for emergency use of CytoSorb in public interest by the Indian health regulator to treat COVID-19 patients who are 18 years of age or older. The licence will be effective until control of the COVID-19 outbreak in the country.</p><p align="justify">Biocon is India's largest and Asia's leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.<br></p>
27-May-2020 Biocon, Maruti Suzuki and Wipro to see some action today <p align="justify"><strong>Biocon's</strong> subsidiary -- Biocon Biologics has received the Drugs Controller General of India's (DCGI) approval for an extracorporeal blood purification (EBP) device CytoSorb to reduce pro-inflammatory cytokines levels in confirmed COVID-19 patients admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure. Biocon Biologics has been granted licence for emergency use of CytoSorb in public interest by the Indian health regulator to treat COVID-19 patients who are 18 years of age or older. The licence will be effective until control of the COVID-19 outbreak in the country.</p><p align="justify"><strong>Maruti Suzuki India</strong> has partnered with ICICI Bank to offer customised auto retail financing solutions across the country. ICICI Bank is a long-standing and preferred partner for retail financing of Maruti Suzuki. Under this association, ICICI Bank is offering a bouquet of attractive finance schemes to the company's customers to help them overcome the current financial challenges. With Maruti Suzuki's over 3,000 outlets and ICICI Bank's extensive network of over 5,380 branches across India, the offer will definitely benefit the customers of all profiles who are willing to buy a car.</p><p align="justify"><strong>Wipro</strong> has launched its Global Channel Partner Program. Wipro's products and platforms have been instrumental in helping clients deal with the impact of the COVID-19 pandemic. Market uncertainties have led organizations to focus on Business Continuity Planning and establish new ways of working. Several Wipro products have helped clients meet their requirements for remote working, business continuity, security, and seamless supply chain and worker safety among others. As the market continues to evolve in the coming months, the company will collaborate with the channel partners to identify new business challenges that can be quickly addressed.</p><p align="justify"><strong>Majesco</strong> has entered into partnership with Millers Mutual to use cloud-native Digital1st Insurance platform to develop their next generation engagement and experience for customers, agents and employees. Majesco's Digital1st Insurance is a ground-breaking, micro-services and API-based platform-asa-service that brings the most cutting-edge business and consumer technology trends to insurance.</p><p align="justify"><strong>ITI</strong> has started manufacturing face shields, with a capacity to produce 5 lakh units per month. The company has started providing face shields to healthcare workers, NGOs, local administration, among others, on complimentary basis, and will provide it to airport staff, police, municipal corporations, state governments and corporates in the second phase. The company is now capable of producing 5 lakh face shields monthly which may be extended to 15 lakh face shields per month in the coming days. </p><p align="justify"><strong>Paisalo Digital</strong> is considering raising funds including issue of Redeemable Non-Convertible Debentures (NCDs) on private placement basis. A meeting of Board of Directors of the company is scheduled to be held on May 30, 2020, to consider and approve the same. </p><p align="justify"><strong>Satia Industries</strong> has signed agreement with Minerals Technologies, (MTI) U.S.A. who will invest completely in building a 42,000 metric ton per year satellite precipitated calcium carbonate (PCC) plant in company's paper mill in Sri Muktsar Sahib, Punjab District, India. The facility is scheduled to begin operation in the second quarter of 2021.<br></p>
19-May-2020 Biocon's arm gets EU GMP Certification for multiple Biosimilars manufacturing facilities in Bengaluru <p align="justify">Biocon's subsidiary -- Biocon Biologics India has received the Certificate of GMP compliance from EMA for multiple Biologics Drug Substance (DS) and Drug Product (DP) manufacturing facilities at Biocon Park, Bengaluru. These facilities are used for the manufacture of DS and DP for Biosimilars: Bevacizumab, Trastuzumab, Pegfilgrastim and secondary packaging of Insulin Glargine for EU markets, and were inspected in March 2020.</p><p align="justify">This approval expands Biocon Biologics' capacities multi-fold to address the growing needs of patients in the EU markets for Trastuzumab commercialized in March 2019 and for Pegfilgrastim expected to be commercialized soon. This certification would further enable the approval process of our biosimilar Bevacizumab, the Marketing Authorization Application for which is currently under review by the European authorities.</p><p align="justify">Biocon is India's largest and Asia's leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide. <br></p>